Genomics Market

Genomics Market by Product & Service (Consumables, Instrument, System & Software), Technology (Sequencing, PCR, Microarray), Study Type (Epigenomics, Biomarker Discovery), Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2028

Report Code: BT 2209 Apr, 2023, by marketsandmarkets.com

The global genomics market in terms of revenue was estimated to be worth $46.2 billion in 2023 and is poised to reach $83.1 billion by 2028, growing at a CAGR of 12.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market include increasing government funding to support genomics projects, rising incidence and prevalence of viral diseases and genetic disorders, growing incidence of cancer and increasing applications of NGS in cancer research, entry of new players and startups in the market, and growing applications of genomics. However, the ethical issues associated with genomics and a dearth of trained professionals are challenging market growth.

Attractive Opportunities in Genomics Market

Genomics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Genomics Market

Genomics Market Dynamics

DRIVER: Increased government funding to support genomics project

In recent years, governments in various countries have made significant investments in the field of genomics. These government investments have played a major role in the development of new technologies. Mentioned below are some recent examples:

  • In December 2022, the UK government announced an investment of USD 190 million (EU 175 million) for genomics research. This research is mainly focused on providing genomic-based diagnosis and treatment options for patients suffering from cancer and children born with treatable rare genetic diseases. The UK government’s initiative “Life Sciences Vision,” launched in 2021, commits to positioning the UK as a global leader in function Genomics.
  • In September 2022, the Australian government’s Department of Health announced an investment of USD 500 million over 10 years in genomics research under the Medical Research Future Fund (MRFF). Through this investment, the government plans to support researchers for genomics in medicine (testing, diagnosis, and treatment) and make a positive impact on the lives of more than 200,000 Australians.
  • In September 2022, the CDC announced funding of USD 90 million for the Pathogen Genomics Centers of Excellence (PGCoE) network, which will foster and develop pathogen genomics, molecular epidemiology, and bioinformatics in the region.

These funding initiatives are expected to increase the usage of genomics products, which will drive overall market growth.

OPPORTUNITY: Use of genomics in specialized/personalized medicine

Growth in the personalized medicine market is set to offer an array of opportunities for players operating in the market. Various pharmaceutical companies are increasingly investing in personalized medicine research. Personalized medicine enables medical practitioners to identify the exact needs of a patient and then prescribe medicines and treatments accordingly. This approach guarantees better care outcomes. Moreover, it is expected that advancements in the field of gene therapy have the potential to replace traditional drugs and surgeries by enabling doctors to treat a disorder by inserting a gene into a patient’s cell.

In September 2022, QIAGEN (Germany) and Neuron23 Inc. (US), an early-stage biotechnology company engaged in developing precision medicine for genetically defined neurological and immunological diseases, entered into an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease. In May 2022, Illumina (US) announced a long-term strategic partnership with Janssen to accelerate the development of precision medicine. Through this partnership, Illumina will support drug discovery with whole-genome sequencing (WGS) and other multi-omic methodologies using Illumina Lab Services. Such developments are indicative of the significant opportunities related to the use of NGS in precision medicine and molecular diagnostics.

CHALLENGE: Secured storage of large volume of sequenced data

The market has witnessed substantial growth in the past few years as a result of scientific breakthroughs. The market is mainly driven by falling prices of sequencing technologies and initiatives by governments in various countries focusing on the use of genomics in personalized medicine. These factors are increasing the adoption of various genomic tests for diagnosis, owing to which a large amount of data is generated.

The human genome consists of approximately 3 billion DNA nucleotides, and it is estimated that approximately 100 GB of data is stored in all the genomes of an individual. According to Nature Magazine, ~30,000 genomes have been sequenced, representing ~3 PB (petabytes) of data. Cloud computing is the most common method of storing this large volume of data and provides access to scientists, clinicians, and consumers across various geographies. However, the security of genetic data collected and stored is a major concern.

Genomics companies are increasingly focusing on reducing the complexity of data interpretation and management. In May 2020, QIAGEN N.V. (Netherlands) introduced a new QCI Interpret One software solution. It joins the QIAGEN Clinical Insights (QCI) portfolio, which has been used to analyze and interpret next-generation sequencing (NGS) data from 1.6 million clinical cases to date. QCI Interpret One enables molecular pathologists to more rapidly and confidently deliver clinically relevant reports designed to improve patient outcomes based on complex genomic testing data. Also, issues regarding storage have increased; it is estimated that over 100 million genomes will have been sequenced by 2025 as part of genomic projects. However, just one human genome sequence produces approximately 200 gigabytes of raw data, and if the sequencing of 100 million genomes by 2025 is to be done, then there will be over 20 billion gigabytes of raw data that is accumulated. Genomics data analysis also needs to be carried out, which generates an additional 100 gigabytes of data per genome and requires massive computing power, which cannot be feasible economically for many biopharmaceutical companies and research institutes. This large-scale generation of data and data storage may become a challenge in the future.

Genomics Market Ecosystem

The market ecosystem comprises of product and service providers and end users such as Hospital and Clinics, Research Centres, Pharmaceutical and Biopharmaceutical companies, and Academic Research Institute. Raw material suppliers and service providers offers various supplies and services, such as instruments, systems, & software, consumables & reagents, services for genomics application such as diagnostics, precesion medicine, drug discovery and development, Agrigenomics, Animal Research, Forensics applications, and Marine Research & Food Applications.

The prominent genomics product and service providers are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche, Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (France), Pacific Biosciences (US), Oxford Nanopore Technologies plc (UK), Abbott Laboratories (US), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf AG (Germany), Merck KGaA (Germany), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), 23andMe, Inc. (US), 10x Genomics (US), Ultima Genomics, Inc. (US), Freenome Holdings, Inc. (US), Helix OpCo, LLC (US), Polaris Genomics (US), Personalis, Inc. (US), Myriad Genetics, Inc. (US), Quest Diagnostics (US), Phalanx Biotech Group (US), and genomiQa Pty Ltd. (Australia).

Ecosystem Analysis: Genomics Market

Genomics Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

Based on product and service, consumables and reagent segment accounted for the largest market share of the genomics industry

Based on product and service, the genomics market is segmented into consumables and reagents, services, and instruments, systems, and software. In 2022, the consumables and reagents segment accounted for the largest share of the market. Consumables are used in large numbers in genomic systems, and their use will continue to increase with the growing number of genomic tests performed across the globe. This is a key factor driving market growth.

Based on technology, sequencing segment accounted for the largest market share of the genomics industry

Based on technology, the genomics market is segmented into sequencing, PCR, microarrays, flow cytometry, and other technologies. In 2022, the sequencing segment accounted for the largest share of the market. The advantages associated with sequencing technologies, such as ultra-high-throughput, scalability, and high speed, enable researchers to perform a wide range of applications, including animal breeding, agriculture, and human genomics.

Based on application, drug discovery and development segment accounted for the largest market share of the genomics industry

Based on application, the genomics market is segmented into drug discovery and development, diagnostics, agriculture and animal research, and other applications. Drug discovery and development was the largest application segment in the market in 2022. The large share of this segment can be attributed to the increasing research on diseases such as cancer and genetic disorders and the decreasing cost of sequencing.

The North American market is projected to contribute the largest share for the genomics industry.

The global genomics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for genomics, with an estimated share in 2022, while Europe is the second-largest market. Favorable initiatives by government and private bodies for the development and adoption of genomics, wide adoption of NGS and PCR-based diagnostics in the region, an increasing number of genomics startups in the region, growing research on cancer, rising awareness of genomics services, and the presence of prominent players in the market, such as Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Danaher Corporation (US), are driving the growth of the market in North America.

Genomics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The genomics market is dominated by a few globally established players such as Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), and QIAGEN N.V. (Germany), among others, are the key players that provided genomics product and service in the last few years. Major focus was given to the deals, expansions, and new product and service launches due to the changing requirements of hospital and clinics, pharmaceutical and biopharmaceutical companies, academic and research institutes, and other end users across the world.

Scope of the Genomics Industry

Report Metric

Details

Market Revenue in 2023

$46.2 billion

Projected Revenue by 2028

$83.1 billion

Revenue Rate

Poised to grow at a CAGR of 12.4%

Market Driver

Increased government funding to support genomics project

Market Opportunity

Use of genomics in specialized/personalized medicine

This report categorizes the genomics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Services

  • Consumables and Reagents
  • Services
  • Instruments, Systems, and Software

By Technology

  • Sequencing
  • PCR
  • Flow Cytometry
  • Microarrays
  • Other Technologies (electrophoresis, southern blotting, isothermal nucleic acid amplification, and in situ hybridization)

By Application

  • Drug Discovery and Development
  • Diagnostics
  • Agriculture and Animal research
  • Other Applications (marine research, biofuel research, food industry, and forensics)

By Study Type

  • Functional Genomics
  • Biomarker Discovery
  • Pathway Analysis
  • Epigenomics
  • Other Study Types (structural genomics, comparative genomics, and mutation genomics)

By End User

  • Hospitals and Clinics
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology companies
  • Other End Users (agrigenomics organizations, marine research organizations, forensic organizations, and food organizations)

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Recent Developments of Genomics Industry

  • In March 2023, Illumina, Inc (US) launched Connected Insights, a new cloud-based software that enables tertiary analysis for clinical next-generation sequencing data. This software will help the genomic profiling (CGP) for advanced tumours along with whole-genome sequencing for rare diseases and other advanced applications.
  • In February 2023, Thermo Fisher Scientific, Inc. (US) launched TrueMark STI Select Panel, a polymerase chain reaction (PCR) test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium for research applications only.
  • In February 2023, Eppendorf AG (Germany) expanded its production facility in China by signing a contract for building a new production site in Shanghai.
  • In October 2022, Oxford Nanopore Technologies (UK) collaborated with 10x Genomics (US) to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 34)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 GENOMICS INDUSTRY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 39)
    2.1 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 PRIMARY RESEARCH
                    FIGURE 2 GENOMICS MARKET SIZE: PRIMARY RESPONDENTS
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 6 MARKET: CAGR PROJECTIONS
          FIGURE 7 GENOMICS INDUSTRY: GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
    2.4 DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 9 GENOMICS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 55)
    4.1 GENOMICS MARKET OVERVIEW 
          FIGURE 14 RISING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 
          FIGURE 15 CONSUMABLES AND REAGENTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 MARKET SHARE, BY APPLICATION, 2023 VS. 2028 
          FIGURE 16 DRUG DISCOVERY AND DEVELOPMENT SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 GENOMICS MARKET SIZE: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
          TABLE 4 GENOMICS INDUSTRY: IMPACT ANALYSIS OF DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing government funding to support genomics projects
                    5.2.1.2 Rising incidence and prevalence of viral diseases and genetic disorders
                                FIGURE 19 BURDEN OF HIV INFECTIONS, BY REGION, 2021
                    5.2.1.3 Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research
                                TABLE 5 CANCER INCIDENCE, 2020 VS. 2040
                    5.2.1.4 Robust investments in genomics startups
                    5.2.1.5 Growing applications of genomics
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Use of genomics in specialized/personalized medicine
           5.2.3 CHALLENGES
                    5.2.3.1 Ethical issues
                    5.2.3.2 Dearth of trained professionals
                    5.2.3.3 Secure storage of large volumes of sequenced data
           5.2.4 TRENDS
                    5.2.4.1 Partnerships and collaborations for technological advancements in genomics
                    5.2.4.2 AI in genomics
    5.3 TECHNOLOGY ANALYSIS 
          TABLE 6 COMPARISON OF SANGER SEQUENCING AND NGS
          TABLE 7 COMPARISON OF PCR TECHNOLOGIES
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 20 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING SEQUENCING AND ANALYSIS PHASES
    5.5 REGULATORY ANALYSIS 
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                                TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
                                TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    5.5.1.2 Canada
           5.5.2 EUROPE
           5.5.3 ASIA PACIFIC
                    5.5.3.1 China
                                TABLE 10 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.5.3.2 Japan
                    5.5.3.3 India
           5.5.4 LATIN AMERICA
           5.5.5 MIDDLE EAST
    5.6 ECOSYSTEM ANALYSIS OF MARKET 
          FIGURE 21 ECOSYSTEM ANALYSIS OF MARKET
    5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
          FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS
    5.8 PRICING ANALYSIS 
           5.8.1 AVERAGE SELLING PRICE OF NGS PRODUCTS
                    TABLE 11 AVERAGE SELLING PRICE OF NGS SYSTEMS, BY KEY PLAYER (2022)
           5.8.2 AVERAGE SELLING PRICE OF PCR PRODUCTS
                    TABLE 12 AVERAGE SELLING PRICE OF PCR SYSTEMS, BY KEY PLAYER (2022)
           5.8.3 AVERAGE SELLING PRICE TREND ANALYSIS
                    FIGURE 23 GENOME SEQUENCING PRICING TREND
    5.9 KEY CONFERENCES AND EVENTS IN 2023–2024 
          TABLE 13 GENOMICS INDUSTRY: LIST OF CONFERENCES AND EVENTS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 14 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 PATENT ANALYSIS 
           FIGURE 24 PATENT APPLICATIONS FOR GENOMICS (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023
           TABLE 15 INDICATIVE LIST OF PATENTS IN GENOMICS (NEXT-GENERATION SEQUENCING) MARKET
           FIGURE 25 PATENT APPLICATIONS FOR GENOMICS (POLYMERASE CHAIN REACTION) MARKET, JANUARY 2012–MARCH 2023
           TABLE 16 INDICATIVE LIST OF PATENTS IN GENOMICS (POLYMERASE CHAIN REACTION) MARKET
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENOMICS PRODUCTS AND SERVICES
           FIGURE 27 BUYING CRITERIA FOR GENOMICS PRODUCTS
 
6 GENOMICS MARKET SIZE, BY PRODUCT & SERVICE (Page No. - 84)
    6.1 INTRODUCTION 
          TABLE 17 MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES AND REAGENTS 
           6.2.1 GROWING APPLICATIONS OF GENOMICS IN VARIOUS FIELDS TO DRIVE ADOPTION
                    TABLE 18 GENOMICS CONSUMABLES AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 19 NORTH AMERICA: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 EUROPE: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: GENOMICS CONSUMABLES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 LACK OF IN-HOUSE EXPERTISE FOR INTERPRETATION OF GENOMICS DATA TO BOOST MARKET FOR OUTSOURCING SERVICES
                    TABLE 22 GENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 NORTH AMERICA: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 EUROPE: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: GENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 INSTRUMENTS, SYSTEMS, AND SOFTWARE 
           6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
                    TABLE 26 LIST OF COMPANIES OFFERING MICROARRAY SCANNERS
                    TABLE 27 GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 NORTH AMERICA: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 EUROPE: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: GENOMICS INSTRUMENTS, SYSTEMS, AND SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 GENOMICS MARKET SHARE, BY TECHNOLOGY (Page No. - 95)
    7.1 INTRODUCTION 
          TABLE 31 GENOMICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 SEQUENCING 
           7.2.1 LAUNCH OF NEW NGS PLATFORMS AND LOWER COST OF SEQUENCING TO DRIVE MARKET
                    TABLE 32 SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 33 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 PCR 
           7.3.1 USE OF PCR TECHNOLOGIES FOR DRUG DISCOVERY TO PROPEL MARKET
                    TABLE 36 PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 37 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 EUROPE: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 FLOW CYTOMETRY 
           7.4.1 APPLICATION OF FLOW CYTOMETRY IN AGRIGENOMICS TO SUPPORT MARKET GROWTH
                    TABLE 40 FLOW CYTOMETRY MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 MICROARRAYS 
           7.5.1 HIGH ADOPTION OF NGS TO LIMIT GROWTH OF MICROARRAY TECHNOLOGIES
                    TABLE 44 MICROARRAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 45 NORTH AMERICA: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 EUROPE: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 OTHER TECHNOLOGIES 
          TABLE 48 OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 49 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 50 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 51 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 GENOMICS MARKET SHARE, BY APPLICATION (Page No. - 109)
    8.1 INTRODUCTION 
          TABLE 52 GENOMICS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 DRUG DISCOVERY AND DEVELOPMENT 
           8.2.1 LARGEST APPLICATION SEGMENT OF MARKET
                    TABLE 53 GENOMICS MARKET SHARE FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 54 NORTH AMERICA: MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 EUROPE: MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 DIAGNOSTICS 
           8.3.1 GROWING APPLICATIONS OF GENOMICS IN DIAGNOSTICS FIELD TO PROPEL MARKET
                    TABLE 57 GRANTS, BY CANCER TYPE (AS OF JANUARY 2023)
                    TABLE 58 GENOMICS MARKET SHARE FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 AGRICULTURE AND ANIMAL RESEARCH 
           8.4.1 GENOMICS HELPS IMPROVE PRODUCTIVITY OF CROPS AND LIVESTOCK
                    TABLE 62GENOMICS  MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 63 NORTH AMERICA: MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 EUROPE: MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 ASIA PACIFIC: MARKET FOR AGRICULTURE AND ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 OTHER APPLICATIONS 
          TABLE 66 GENOMICS MARKET SHARE FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 67 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 68 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 69 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 GENOMICS MARKET TRENDS, BY STUDY TYPE (Page No. - 122)
    9.1 INTRODUCTION 
          TABLE 70 GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
    9.2 FUNCTIONAL GENOMICS 
           9.2.1 INCREASED GENOMIC STUDIES TO POSITIVELY INFLUENCE MARKET GROWTH
                    TABLE 71 GENOMICS MARKET TRENDS FOR FUNCTIONAL GENOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 BIOMARKER DISCOVERY 
           9.3.1 RISE IN PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
                    TABLE 75 GENOMICS MARKET TRENDS FOR BIOMARKER DISCOVERY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 76 NORTH AMERICA: MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 ASIA PACIFIC: MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 PATHWAY ANALYSIS 
           9.4.1 DEVELOPMENT OF NEXT-GENERATION THERAPIES TO DRIVE MARKET
                    TABLE 79 GENOMICS MARKET TRENDS FOR PATHWAY ANALYSIS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 80 NORTH AMERICA: MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 EUROPE: MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 ASIA PACIFIC: MARKET FOR PATHWAY ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 EPIGENOMICS 
           9.5.1 INCREASE IN INVESTMENTS FOR EPIGENETICS RESEARCH TO SUPPORT MARKET GROWTH
                    TABLE 83 GENOMICS MARKET TRENDS FOR EPIGENOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 84 NORTH AMERICA: MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 85 EUROPE: MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 ASIA PACIFIC: MARKET FOR EPIGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.6 OTHER STUDY TYPES 
          TABLE 87 GENOMICS MARKET OVERVIEW FOR OTHER STUDY TYPES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 88 NORTH AMERICA: MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 89 EUROPE: MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 90 ASIA PACIFIC: MARKET FOR OTHER STUDY TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 GENOMICS MARKET OVERVIEW, BY END USER (Page No. - 136)
     10.1 INTRODUCTION 
             TABLE 91 GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS AND CLINICS 
             10.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSIS AND TREATMENT TO DRIVE MARKET
                        TABLE 92 GENOMICS MARKET OVERVIEW FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 93 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 94 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 95 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 ACADEMIC AND RESEARCH INSTITUTES 
             10.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USE OF GENOMICS PRODUCTS AMONG ACADEMIC AND RESEARCH INSTITUTES
                        TABLE 96 GENOMICS MARKET OVERVIEW FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 97 NORTH AMERICA: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 98 EUROPE: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 99 ASIA PACIFIC: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 
             10.4.1 GROWING IMPORTANCE OF BIOMARKERS FOR DRUG DISCOVERY TO DRIVE ADOPTION OF GENOMICS PRODUCTS AND SERVICES AMONG PHARMA AND BIOTECH COMPANIES
                        TABLE 100 GENOMICS MARKET ANALYSIS FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 101 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 102 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 103 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 104 GENOMICS MARKET ANALYSIS FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 105 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 106 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 107 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 GENOMICS MARKET ANALYSIS, BY REGION (Page No. - 148)
     11.1 INTRODUCTION 
             TABLE 108 MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 28 NORTH AMERICA: GENOMICS MARKET SNAPSHOT
             TABLE 109 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 110 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 111 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 112 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 113 NORTH AMERICA: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
             TABLE 114 NORTH AMERICA: GENOMICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US dominates North American genomics market
                                      TABLE 115 US: GENOMICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 116 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 117 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 118 US: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 119 US: GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Increasing research in genomics to drive market
                                      TABLE 120 CANADA: GENOMICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 121 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 122 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 123 CANADA: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 124 CANADA: GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             TABLE 125 EUROPE: GENOMICS MARKET PREDICTION, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 126 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 127 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 128 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 129 EUROPE: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
             TABLE 130 EUROPE: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing awareness of NGS to boost market growth
                                      TABLE 131 GERMANY: GENOMICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 132 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 133 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 134 GERMANY: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 135 GERMANY: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Availability of government funding and strategic collaborations with biotech firms to boost market growth
                                      TABLE 136 UK: GENOMICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 137 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 138 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 139 UK: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 140 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Increasing government investments in genomics to drive market
                                      TABLE 141 FRANCE: GENOMICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 142 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 143 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 144 FRANCE: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 145 FRANCE: GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Favorable funding scenario to drive adoption of sequencing technologies
                                      TABLE 146 ITALY: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 147 ITALY: GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 148 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 149 ITALY: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 150 ITALY: GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Focus on expanding genomic research to support market growth
                                      TABLE 151 SPAIN: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 152 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 153 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 154 SPAIN: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 155 SPAIN: GENOMICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 156 REST OF EUROPE: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 157 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 158 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 159 REST OF EUROPE: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                        TABLE 160 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 29 ASIA PACIFIC: GENOMICS MARKET SNAPSHOT
             TABLE 161 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 162 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 163 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 164 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 165 ASIA PACIFIC: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
             TABLE 166 ASIA PACIFIC: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Fastest-growing market in Asia Pacific
                                      TABLE 167 CHINA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 168 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 169 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 170 CHINA: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 171 CHINA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Growing NGS market to support market growth
                                      TABLE 172 JAPAN: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 173 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 174 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 175 JAPAN: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 176 JAPAN: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Emergence of local players and increasing adoption of genomics technologies to aid market growth
                                      TABLE 177 INDIA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 178 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 179 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 180 INDIA: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 181 INDIA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Increase in precision medicine and academic studies to propel market growth
                                      TABLE 182 AUSTRALIA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 183 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 184 AUSTRALIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 185 AUSTRALIA: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 186 AUSTRALIA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Government initiatives to favor market growth
                                      TABLE 187 SOUTH KOREA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 188 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 189 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 190 SOUTH KOREA: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 191 SOUTH KOREA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 192 REST OF ASIA PACIFIC: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 193 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 194 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 195 REST OF ASIA PACIFIC: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                        TABLE 196 REST OF ASIA PACIFIC: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.7 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             11.5.1 EXPANSION OF KEY PLAYERS TO BOOST MARKET GROWTH
                        TABLE 197 LATIN AMERICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 198 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 199 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 200 LATIN AMERICA: MARKET, BY STUDY TYPE, 2021–2028 (USD MILLION)
                        TABLE 201 LATIN AMERICA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST AND AFRICA 
             11.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING HIV & CANCER INCIDENCE TO DRIVE MARKET
                        TABLE 202 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 203 MIDDLE EAST AND AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 204 MIDDLE EAST AND AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 205 MIDDLE EAST AND AFRICA: GENOMICS INDUSTRY, BY STUDY TYPE, 2021–2028 (USD MILLION)
                        TABLE 206 MIDDLE EAST AND AFRICA: GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 209)
     12.1 INTRODUCTION 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 30 GENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     12.3 REVENUE ANALYSIS 
             FIGURE 31 REVENUE ANALYSIS OF KEY COMPANIES, 2020–2022
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 32 GENOMICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
             TABLE 207 GENOMICS INDUSTRY: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 33 GENOMICS MARKET: COMPANY EVALUATION MATRIX, 2022
     12.6 COMPETITIVE BENCHMARKING 
             12.6.1 OVERALL COMPANY FOOTPRINT (32 COMPANIES)
                        TABLE 208 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
             12.6.2 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (32 COMPANIES)
                        TABLE 209 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
             12.6.3 REGIONAL FOOTPRINT OF COMPANIES (32 COMPANIES)
                        TABLE 210 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     12.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 STARTING BLOCKS
             12.7.3 RESPONSIVE COMPANIES
             12.7.4 DYNAMIC COMPANIES
FIGURE 34 GENOMICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
     12.8 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 
TABLE 211 GENOMICS INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
     12.9 COMPETITIVE SCENARIO AND TRENDS 
             12.9.1 PRODUCT/SERVICE LAUNCHES
                        TABLE 212 GENOMICS INDUSTRY: KEY PRODUCT/SERVICE LAUNCHES, JANUARY 2020–APRIL 2023
             12.9.2 DEALS
                        TABLE 213 GENOMICS INDUSTRY: KEY DEALS, JANUARY 2020–APRIL 2023
             12.9.3 OTHER DEVELOPMENTS
                        TABLE 214 GENOMICS MARKET: OTHER KEY DEVELOPMENTS, JANUARY 2020–APRIL 2023
 
13 COMPANY PROFILES (Page No. - 226)
     13.1 MAJOR PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 ILLUMINA, INC.
                        TABLE 215 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             13.1.2 THERMO FISHER SCIENTIFIC INC.
                        TABLE 216 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.3 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 217 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.4 DANAHER CORPORATION
                        TABLE 218 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.5 QIAGEN N.V.
                        TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
             13.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 220 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.7 PERKINELMER INC.
                        TABLE 221 PERKINELMER INC.: BUSINESS OVERVIEW
                        FIGURE 41 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
             13.1.8 BIO-RAD LABORATORIES, INC.
                        TABLE 222 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.9 EUROFINS SCIENTIFIC
                        TABLE 223 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 43 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             13.1.10 PACIFIC BIOSCIENCES
                        TABLE 224 PACIFIC BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 44 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022)
             13.1.11 OXFORD NANOPORE TECHNOLOGIES PLC
                        TABLE 225 OXFORD NANOPORE TECHNOLOGIES PLC: BUSINESS OVERVIEW
                        FIGURE 45 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2022)
             13.1.12 TAKARA BIO INC.
                        TABLE 226 TAKARA BIO INC.: BUSINESS OVERVIEW
                        FIGURE 46 TAKARA BIO INC.: COMPANY SNAPSHOT (2022)
             13.1.13 BGI GROUP
                        TABLE 227 BGI GROUP: BUSINESS OVERVIEW
             13.1.14 EPPENDORF AG
                        TABLE 228 EPPENDORF AG: BUSINESS OVERVIEW
                        FIGURE 47 EPPENDORF AG: COMPANY SNAPSHOT (2021)
             13.1.15 MERCK KGAA
                        TABLE 229 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 48 MERCK KGAA: COMPANY SNAPSHOT (2022)
             13.1.16 BECTON, DICKINSON AND COMPANY
                        TABLE 230 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             13.1.17 ABBOTT LABORATORIES
                        TABLE 231 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 50 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.18 23ANDME, INC.
                        TABLE 232 23ANDME, INC.: BUSINESS OVERVIEW
                        FIGURE 51 23ANDME, INC.: COMPANY SNAPSHOT (2021)
             13.1.19 10X GENOMICS
                        TABLE 233 10X GENOMICS: BUSINESS OVERVIEW
                        FIGURE 52 10X GENOMICS: COMPANY SNAPSHOT (2022)
             13.1.20 NEW ENGLAND BIOLABS
                        TABLE 234 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW
             13.1.21 PROMEGA CORPORATION
                        TABLE 235 PROMEGA CORPORATION: BUSINESS OVERVIEW
             13.1.22 CREATIVE BIOGENE
                        TABLE 236 CREATIVE BIOGENE: BUSINESS OVERVIEW
             13.1.23 NOVOGENE CO., LTD.
                        TABLE 237 NOVOGENE CO., LTD.: BUSINESS OVERVIEW
             13.1.24 ULTIMA GENOMICS, INC.
                        TABLE 238 ULTIMA GENOMICS, INC. BUSINESS OVERVIEW
             13.1.25 FREENOME HOLDINGS, INC.
                        TABLE 239 FREENOME HOLDINGS, INC.: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 QUEST DIAGNOSTICS
             13.2.2 MYRIAD GENETICS, INC.
             13.2.3 PERSONALIS, INC.
             13.2.4 HELIX OPCO, LLC
             13.2.5 POLARIS GENOMICS
             13.2.6 PHALANX BIOTECH GROUP
             13.2.7 GENOMIQA PTY LTD
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 394)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 
 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global genomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from International Chromosome and Genome Society (ICGS), International Mammalian Genome Society (IMGS), International Agency for Research on Cancer (IARC), National Human Genome Research Institute (NHGRI), Centers for Common Disease Genomics (CCDG), National Institutes of Health (NIH), International Service for the Acquisition of Agri-Biotech Applications (ISAAA), Genome Canada, European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, Centre for Cellular & Molecular Biology (CCMB), Japan Agency for Medical Research and Development (AMED), Kinghorn Centre for Clinical Genomics (KCCG), King Abdulaziz City for Science and Technology (KACST), São Paulo Research Foundation (FAPESP), Brazilian Agricultural Research Corporation (Embrapa). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global genomics market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global genomics market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from hospitals and clinics, academic and research institutes, pharmaceutical and biopharmaceutical industries, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

 The following is a breakdown of the primary respondents:

Genomics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the genomics market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the genomics market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the genomics business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.   

Bottom-up approach: Company Revenue Analysis

Genomics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: MnM Repository

For estimating the genomics market, related market reports in the MnM repository, including the next-generation sequencing services market, PCR technologies market, microarray market, flow cytometry market, electrophoresis market, isothermal nucleic acid amplification technology market, and in situ hybridization market, were considered. The global and regional market values of the genomics and dependent submarkets were extracted from the MnM repository and validated through secondary and primary research. The final global market size was triangulated through the average of all approaches and validated through primary interviews with industry experts.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition:

Genomics is a branch of molecular biology that involves the study of the structure, function, evolution, and mapping of genomes. It applies the techniques of genetics, molecular biology, and bioinformatics to sequence, assemble, and analyze the function and structure of the genome of a selected organism for the purpose of analysis. Genomics is widely used in diagnostics, drug discovery and development, animal and agricultural research, forensics, and aquaculture research, among others.

Key Stakeholders

  • Genomics Instrument/System Manufacturing Companies
  • Suppliers and Distributors of Genomic Instruments/Systems, Consumables, and Services
  • Hospitals, Diagnostic Centers, and Medical Colleges
  • Research Institutes
  • Teaching Hospitals and Academic Medical Centers (AMCs)
  • Government Bodies/Municipal Corporations
  • Business Research Firms
  • Venture Capitalists
  • Pharmaceutical and Biopharmaceutical Companies

Report Objectives

  • To define, describe, and forecast the genomics market on the basis of product & service, application, technology, study type, end user, and region
  • To provide detailed information regarding the factors influencing the market growth (such as drivers, opportunities, challenges, and trends)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall genomics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To profile the key players in the global genomics market and comprehensively analyze their core competencies and market rankings
  • To forecast the size of the market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To track and analyze competitive developments such as product and service launches, expansions, acquisitions, partnerships, collaborations, and agreements in the genomics market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the RoE genomics market, by country
  • Further breakdown of the RoAPAC genomics market, by country
  • Further breakdown of the RoLA and MEA genomics markets, by country

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)

Segment Analysis

  • Further breakdown of the technology segment as per the product and service portfolio of prominent players operating in the market.  
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2209
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Genomics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback